1. Home
  2. KDLY vs RLMD Comparison

KDLY vs RLMD Comparison

Compare KDLY & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KDLY
  • RLMD
  • Stock Information
  • Founded
  • KDLY 2019
  • RLMD 2004
  • Country
  • KDLY United States
  • RLMD United States
  • Employees
  • KDLY N/A
  • RLMD N/A
  • Industry
  • KDLY
  • RLMD Biotechnology: Pharmaceutical Preparations
  • Sector
  • KDLY
  • RLMD Health Care
  • Exchange
  • KDLY NYSE
  • RLMD Nasdaq
  • Market Cap
  • KDLY 10.9M
  • RLMD 11.5M
  • IPO Year
  • KDLY 2024
  • RLMD N/A
  • Fundamental
  • Price
  • KDLY $13.86
  • RLMD $0.40
  • Analyst Decision
  • KDLY
  • RLMD Hold
  • Analyst Count
  • KDLY 0
  • RLMD 4
  • Target Price
  • KDLY N/A
  • RLMD $4.25
  • AVG Volume (30 Days)
  • KDLY 5.3M
  • RLMD 4.5M
  • Earning Date
  • KDLY 05-08-2025
  • RLMD 05-12-2025
  • Dividend Yield
  • KDLY N/A
  • RLMD N/A
  • EPS Growth
  • KDLY N/A
  • RLMD N/A
  • EPS
  • KDLY N/A
  • RLMD N/A
  • Revenue
  • KDLY $2,470,466.00
  • RLMD N/A
  • Revenue This Year
  • KDLY N/A
  • RLMD N/A
  • Revenue Next Year
  • KDLY N/A
  • RLMD N/A
  • P/E Ratio
  • KDLY N/A
  • RLMD N/A
  • Revenue Growth
  • KDLY N/A
  • RLMD N/A
  • 52 Week Low
  • KDLY $0.65
  • RLMD $0.24
  • 52 Week High
  • KDLY $5.25
  • RLMD $4.47
  • Technical
  • Relative Strength Index (RSI)
  • KDLY N/A
  • RLMD 51.73
  • Support Level
  • KDLY N/A
  • RLMD $0.36
  • Resistance Level
  • KDLY N/A
  • RLMD $0.44
  • Average True Range (ATR)
  • KDLY 0.00
  • RLMD 0.08
  • MACD
  • KDLY 0.00
  • RLMD -0.00
  • Stochastic Oscillator
  • KDLY 0.00
  • RLMD 26.98

About KDLY KINDLY MD INC

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Share on Social Networks: